Dr brodie baltimore md

She continued her research with 4-OHA after coming to UMSOM in , spearheading its development through clinical trials into a treatment for breast cancer. Released as Formestane for worldwide use in , it was the first new agent in a decade specifically designed to treat breast cancer. Early on, few other scientists gave her research much credence.

She tried to interest pharmaceutical companies, but many thought that her work was unnecessary and that chemotherapy was the answer. It was only through her persistence that her experimental compound ever made it to clinical trial. She ended up making small batches of the aromatase inhibitor in her laboratory at UMSOM and shipping it to the Royal Marsden Hospital in London where it was given to 11 women with advanced breast cancer as part of a clinical trial.

Recognized Internationally Among her many awards are the prestigious Charles F. Komen Breast Cancer Foundation in But perhaps her most understated, and yet equally important role was that of a mentor. She developed novel therapeutics for breast cancer patients with estrogen-driven cancers and it completely revolutionized how patients are treated. Her early studies recognizing the significance of estrogen in these types of breast cancers, and her foresight to develop inhibitors that block estrogen production have cemented her as one of the leading pioneers of breast cancer research and therapeutic development.

Yet despite the prestige her tremendous contributions awarded her, Dr. Brodie remained an effective and engaged mentor to her graduate students. Gupta remembers Dr. Brodie for the positive and encouraging way she seemed to handle every situation.

JAMA ; 21 Lancet Respir Med ;7 2 Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med ; Treatment limitations in the era of ECMO. Lancet Resp Med ;5 10 She was Brodie's research revolutionized the treatment of hormone-dependent breast cancer worldwide. She pioneered the development of aromatase inhibitors, which are now considered among the most important contributions toward treating estrogen-driven breast cancer, the most common form of breast cancer in postmenopausal women.

Her work developing aromatase inhibitors was a paradigm-shifting effort that began in the s and was designed to reduce the level of estrogen in the body and thereby block the growth of cancer cells. Aromatase is an enzyme that plays a key role in the biosynthesis of estrogen, which fuels the growth of cancer cells.

She was extraordinarily humble about her achievements and never sought attention for what she accomplished. Brodie began investigating compounds to inhibit aromatase while at the Worcester Foundation for Experimental Biology in Shrewsbury, Mass. She continued her research with 4-OHA after coming to UMSOM in , spearheading its development through clinical trials into a treatment for breast cancer.